BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 37047827)

  • 1. Design, Synthesis and Biological Evaluation of 6-(Imidazo[1,2-a]pyridin-6-yl)quinazoline Derivatives as Anticancer Agents via PI3Kα Inhibition.
    Li M; Wang D; Li Q; Luo F; Zhong T; Wu H; Xiong L; Yuan M; Su M; Fan Y
    Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and biological evaluation of novel 6-(pyridin-3-yl) quinazolin-4(3H)-one derivatives as potential anticancer agents via PI3K inhibition.
    Yang H; Li Q; Su M; Luo F; Liu Y; Wang D; Fan Y
    Bioorg Med Chem; 2021 Sep; 46():116346. PubMed ID: 34403956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel 4-aminoquinazoline derivatives induce growth inhibition, cell cycle arrest and apoptosis via PI3Kα inhibition.
    Fan YH; Ding HW; Liu DD; Song HR; Xu YN; Wang J
    Bioorg Med Chem; 2018 May; 26(8):1675-1685. PubMed ID: 29475582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure optimization, synthesis, and biological evaluation of 6-(2-amino-1H-benzo[d]imidazole-6-yl)-quinazolin-4(3H)-one derivatives as potential multi-targeted anticancer agents via Aurora A/ PI3K/BRD4 inhibition.
    Fan Y; Luo F; Su M; Li Q; Zhong T; Xiong L; Li M; Yuan M; Wang D
    Bioorg Chem; 2023 Mar; 132():106352. PubMed ID: 36682147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and evaluation of 2, 6, 8-substituted Imidazopyridine derivatives as potent PI3K
    Chen R; Wang Z; Sima L; Cheng H; Luo B; Wang J; Guo B; Mao S; Zhou Z; Peng J; Tang L; Liu X; Liao W
    J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2155638. PubMed ID: 36650905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of 2-(2-aminopyrimidin-5-yl)-4-morpholino-N-(pyridin-3-yl)quinazolin-7-amines as novel PI3K/mTOR inhibitors and anticancer agents.
    Peng W; Tu ZC; Long ZJ; Liu Q; Lu G
    Eur J Med Chem; 2016 Jan; 108():644-654. PubMed ID: 26731167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, biological evaluation, and in silico studies of 2-aminobenzothiazole derivatives as potent PI3Kα inhibitors.
    Haider K; Ahmad K; Najmi AK; Das S; Joseph A; Shahar Yar M
    Arch Pharm (Weinheim); 2022 Oct; 355(10):e2200146. PubMed ID: 35665957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and biological evaluation of novel 3-substituted imidazo[1,2-a]pyridine and quinazolin-4(3H)-one derivatives as PI3Kα inhibitors.
    Fan YH; Li W; Liu DD; Bai MX; Song HR; Xu YN; Lee S; Zhou ZP; Wang J; Ding HW
    Eur J Med Chem; 2017 Oct; 139():95-106. PubMed ID: 28800461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and antitumor activities evaluation of m-(4-morpholinoquinazolin-2-yl)benzamides in vitro and in vivo.
    Wang XM; Xin MH; Xu J; Kang BR; Li Y; Lu SM; Zhang SQ
    Eur J Med Chem; 2015; 96():382-95. PubMed ID: 25911625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis, anticancer and antimicrobial evaluation of new benzofuran based derivatives: PI3K inhibition, quorum sensing and molecular modeling study.
    El-Khouly OA; Henen MA; El-Sayed MA; Shabaan MI; El-Messery SM
    Bioorg Med Chem; 2021 Feb; 31():115976. PubMed ID: 33388654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of novel 2,4-disubstituted quinazoline derivatives targeting H1975 cells via EGFR-PI3K signaling pathway.
    Wang Z; Liu L; Dai H; Si X; Zhang L; Li E; Yang Z; Chao G; Zheng J; Ke Y; Lihong S; Zhang Q; Liu H
    Bioorg Med Chem; 2021 Aug; 43():116265. PubMed ID: 34192644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and biological evaluation of novel thieno[3,2-d]pyrimidine and quinazoline derivatives as potent antitumor agents.
    Hu H; Dong Y; Li M; Wang R; Zhang X; Gong P; Zhao Y
    Bioorg Chem; 2019 Sep; 90():103086. PubMed ID: 31280016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ligand-Based Drug Design: Synthesis and Biological Evaluation of Substituted Benzoin Derivatives as Potential Antitumor Agents.
    Sabbah DA; Ibrahim AH; Talib WH; Alqaisi KM; Sweidan K; Bardaweel SK; Sheikha GA; Zhong HA; Al-Shalabi E; Khalaf RA; Mubarak MS
    Med Chem; 2019; 15(4):417-429. PubMed ID: 30207238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alkylsulfonamide-containing quinazoline derivatives as potent and orally bioavailable PI3Ks inhibitors.
    Hei YY; Zhang SQ; Feng Y; Wang J; Duan W; Zhang H; Mao S; Sun H; Xin M
    Bioorg Med Chem; 2019 Oct; 27(20):114930. PubMed ID: 31176568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.
    Chang J; Ren H; Zhao M; Chong Y; Zhao W; He Y; Zhao Y; Zhang H; Qi C
    Eur J Med Chem; 2017 Sep; 138():669-688. PubMed ID: 28711702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and biological evaluation of novel 4-aminoquinazolines as dual target inhibitors of EGFR-PI3Kα.
    Ding HW; Deng CL; Li DD; Liu DD; Chai SM; Wang W; Zhang Y; Chen K; Li X; Wang J; Song SJ; Song HR
    Eur J Med Chem; 2018 Feb; 146():460-470. PubMed ID: 29407971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DW09849, a selective phosphatidylinositol 3-kinase (PI3K) inhibitor, prevents PI3K signaling and preferentially inhibits proliferation of cells containing the oncogenic mutation p110α (H1047R).
    Liu JL; Gao GR; Zhang X; Cao SF; Guo CL; Wang X; Tong LJ; Ding J; Duan WH; Meng LH
    J Pharmacol Exp Ther; 2014 Mar; 348(3):432-41. PubMed ID: 24361696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-Based Design: Synthesis, X-ray Crystallography, and Biological Evaluation of N-Substituted-4-Hydroxy-2-Quinolone-3-Carboxamides as Potential Cytotoxic Agents.
    Sabbah DA; Hishmah B; Sweidan K; Bardaweel S; AlDamen M; Zhong HA; Abu Khalaf R; Hasan Ibrahim A; Al-Qirim T; Abu Sheikha G; Mubarak MS
    Anticancer Agents Med Chem; 2018; 18(2):263-276. PubMed ID: 28901259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and biological evaluation of novel pyrazinone derivatives as PI3K/HDAC dual inhibitors.
    Wang ZX; Wang S; Qiao XP; Li WB; Shi JT; Wang YR; Chen SW
    Bioorg Med Chem; 2022 Nov; 74():117067. PubMed ID: 36272186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and Synthesis of some new 2,4,6-trisubstituted quinazoline EGFR inhibitors as targeted anticancer agents.
    Allam HA; Aly EE; Farouk AKBAW; El Kerdawy AM; Rashwan E; Abbass SES
    Bioorg Chem; 2020 May; 98():103726. PubMed ID: 32171987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.